Suzhou苏州
Tier 2 - Major CityChina's top biotech hub (BioBay) and a major manufacturing center for medical devices, advanced materials, and precision instruments. Often has a higher GDP than many tier-1 cities.
GDP
$345B
2023
Population
12.95M
residents
Industry Output
¥200B
all sectors combined
Sectors Active
3
frontier tech sectors
Key Facts
- BioBay (BioBAY) hosts 500+ biotech companies
- Leading center for innovative drug development in China
- Suzhou Industrial Park (SIP) is a model for Singapore-style development
- GDP exceeds many tier-1 cities despite tier-2 classification
Manufacturing Sectors
Biotech & Biopharma
生物技术与生物医药
Innovative drugs (PD-1, ADC), CRO/CDMO, gene therapy
Advanced Medical Devices
高端医疗器械
IVD (in-vitro diagnostics), surgical instruments, medical imaging
Advanced Materials
新材料
Nanomaterials, specialty chemicals, electronic materials
Major Companies
Leading innovative biopharmaceutical company, known for PD-1 antibody and partnership with Eli Lilly.
Founded 2011
Pioneer in reproductive genetics and molecular diagnostics, offering next-generation sequencing-based preimplantation genetic testing.
Founded 2012
GenScript ProBio (Suzhou)
金斯瑞蓬勃(苏州)
Global CDMO for cell and gene therapy, with major production and development facilities in BioBay.
Founded 2002
History & Context
Suzhou Industrial Park (SIP), a joint China-Singapore project launched in 1994, became a model for high-tech park development. In the 2010s, BioBay (within SIP) emerged as China's answer to Boston's biotech cluster. Hundreds of returnee scientists from US pharma companies set up innovative drug companies, attracted by low costs, talent access, and aggressive local incentives. The city has also built strong positions in nanotechnology, medical devices, and precision manufacturing.